GeoVax Labs Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $985,460. The enterprise value is -$915,033.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 544,453 shares outstanding. The number of shares has increased by 617.68% in one year.
| Current Share Class | 544,453 |
| Shares Outstanding | 544,453 |
| Shares Change (YoY) | +617.68% |
| Shares Change (QoQ) | +106.90% |
| Owned by Insiders (%) | 4.22% |
| Owned by Institutions (%) | 6.40% |
| Float | 355,948 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.46 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -603.27% and return on invested capital (ROIC) is -363.42%.
| Return on Equity (ROE) | -603.27% |
| Return on Assets (ROA) | -225.63% |
| Return on Invested Capital (ROIC) | -363.42% |
| Return on Capital Employed (ROCE) | -1,422.00% |
| Weighted Average Cost of Capital (WACC) | 20.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$961,206 |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.27% in the last 52 weeks. The beta is 3.86, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.86 |
| 52-Week Price Change | -99.27% |
| 50-Day Moving Average | 5.76 |
| 200-Day Moving Average | 25.27 |
| Relative Strength Index (RSI) | 16.06 |
| Average Volume (20 Days) | 625,442 |
Short Selling Information
The latest short interest is 175,903, so 32.31% of the outstanding shares have been sold short.
| Short Interest | 175,903 |
| Short Previous Month | 270,211 |
| Short % of Shares Out | 32.31% |
| Short % of Float | 49.42% |
| Short Ratio (days to cover) | 0.21 |
Income Statement
| Revenue | n/a |
| Gross Profit | -12.83M |
| Operating Income | -18.33M |
| Pretax Income | -18.26M |
| Net Income | -18.26M |
| EBITDA | -18.28M |
| EBIT | -18.33M |
| Earnings Per Share (EPS) | -$98.30 |
Full Income Statement Balance Sheet
The company has $2.15 million in cash and $250,453 in debt, with a net cash position of $1.90 million or $3.49 per share.
| Cash & Cash Equivalents | 2.15M |
| Total Debt | 250,453 |
| Net Cash | 1.90M |
| Net Cash Per Share | $3.49 |
| Equity (Book Value) | 1.15M |
| Book Value Per Share | 2.73 |
| Working Capital | 978,595 |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -16.50M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 50,924 |
| Net Borrowing | n/a |
| Free Cash Flow | -16.50M |
| FCF Per Share | -$30.30 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -617.68% |
| Shareholder Yield | -617.68% |
| Earnings Yield | -5,431.19% |
| FCF Yield | -1,674.17% |
Analyst Forecast
The average price target for GeoVax Labs is $240.00, which is 13,159.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $240.00 |
| Price Target Difference | 13,159.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on November 11, 2026. It was a reverse split with a ratio of 1:24.
| Last Split Date | Nov 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:24 |
Scores
GeoVax Labs has an Altman Z-Score of -82.83 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -82.83 |
| Piotroski F-Score | 1 |